Where does OCRA's clinical trial data come from?

OCRA indexes clinical trials from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Trials are matched to diseases, investigators, and funded research tracked across the platform.

How do I find clinical trials for ovarian cancer?

Search by condition, treatment type, trial phase, or NCT identifier. Each trial page shows current status, eligibility criteria, study locations, and a direct link to the ClinicalTrials.gov source record.

How often is clinical trial data updated?

Trial data is refreshed through periodic ingestion from the ClinicalTrials.gov v2 API. Status changes, new enrollments, and newly registered trials are captured during each update cycle.

Epidemiology and Risk Factors of Uterine Fibroids in China

NCT05840042NOT_YET_RECRUITINGOBSERVATIONAL

Summary

Uterine fibroids are the most common form of benign uterine tumors in the uterine muscle layer, which had a certain rate of malignancy, but it is rare. The prevalence of uterine fibroids estimates range from 4.5% to 68.6% depending on study population and diagnostic methodology. The prevalence of fibroids has been historically underestimated by epidemiologic studies which focused mainly on symptomatic women, leaving behind a large population of asymptomatic women and women who underreport their symptoms. What investigators don't know was which women who have fibroids will develop clinical symptoms and which women who have an operation of myomectomy will relapse. The purpose of this study is to investigate the prevalence, incidence and risk factors for the development of uterine fibroids in Chinese women.

Key Facts

Lead Sponsor

Shixuan Wang

Enrollment

20000

Start Date

2023-06-19

Completion Date

2025-12-31

Study Type

OBSERVATIONAL

Official Title

Epidemiology and Risk Factors of Uterine Fibroids in China

Conditions

Uterine Fibroid

Eligibility

Age Range

18 Years+

Sex

FEMALE

Inclusion Criteria:

* Current place of residence≥ 6 months;
* No serious mental illness or mental abnormality;
* Those who agree to participate in this survey and cooperate in completing the questionnaire.

Exclusion Criteria:

\-

Outcome Measures

Primary Outcomes

Prevalence of uterine fibroids in China

Time frame: Baseline

Secondary Outcomes

Incidence of uterine fibroids in China

Time frame: Two follow-ups over a three-year period

Risk factors of development of uterine fibroids in China

Associated risk factors for recurrence, infertility and malignancy of uterine fibroids in China

Time frame: Two follow-ups over a three-year period

Linked Papers

2024-01-17

Status and treatment of patients with uterine fibroids in hospitals in central China: a retrospective study from 2018 to 2021

ObjectiveTo evaluate the hospitalised patients with uterine fibroids (UFs) and describe treatment patterns in hospital-treated patients in central China from 2018 to 2021.DesignA retrospective analysis.SettingThe gynaecology departments of class A and class B secondary and tertiary hospitals in Hubei Province, China.Participants101 008 patients diagnosed with UFs from 1 January 2018 to 31 December 2021.ResultsThe hospitalised patients with UFs increased with age, reaching a peak at ages 45–49 years and then gradually decreasing. Among these patients, 19.05% had anaemia symptoms. Women aged 25–29 years were more likely to be treated with laparoscopic myomectomy (62.22%), while women aged 20–24 years tend to choose open myomectomy (34.58%). Women over age 45 years who had entered perimenopause tended to be treated with laparoscopic hysterectomy (64.85% for those aged 65–69 years). Patients with fibroid with moderate-to-severe anaemia mostly chose hysterectomy. As a whole, the proportion of patients who chose laparoscopic hysterectomy was similar to that of patients who chose laparoscopic myomectomy (31.38% vs 31.14%). Only 2.08% of UFs were treated with high-frequency MRI-guided focused ultrasound surgery (MRgFUS). The number of patients who choose laparoscopic surgery or MRgFUS treatment was increasing year by year. After stratifying by hospital grade, we found that women treated at class A tertiary hospitals were more likely to have laparoscopic than open surgery (66.12% vs 31.26%). At class B secondary hospitals, 61.9% of the patients underwent myomectomy. By contrast, hysterectomy was used to treat the majority of patients at class A secondary hospitals and class B tertiary hospitals (57.79% and 57.57%, respectively). Use of MRgFUS was mainly concentrated within class A tertiary hospitals.ConclusionUFs affect mainly women in childbearing period. Most patients chose to receive treatment at class A tertiary hospitals, among which laparoscopic myomectomy was the mainstream surgical method for patients in Hubei Province.Trial registration numberNCT05840042.

Linked Investigators

Shixuan Wang

Wenwen Wang